Flora Fertility Raises $5M Seed Round to Scale Individually-Owned Fertility Insurance Platform

New updates have been reported about Flora Fertility.

Flora Fertility has secured a $5 million USD seed round to accelerate its individually-owned fertility insurance platform, positioning the company to expand U.S. market reach and prepare for entry into Canada. The round was led by InsurTech-focused investor ManchesterStory, with participation from Slauson & Co., TruStage Ventures, BDC Capital, Marathon Fund, Adara Venture Capital, and strategic angels, building on backing from earlier investors.

Management plans to deploy the capital to reinforce Flora’s first-mover position in private fertility insurance, an emerging niche at the intersection of InsurTech and women’s health that targets a largely untapped, consumer-paid benefit market. The company aims to broaden access to proactive, portable fertility coverage at a time when infertility affects roughly one in six people globally and treatment costs can range from $30,000 to $50,000, with limited traditional coverage.

Flora’s product is structured as individually-owned insurance, decoupled from employers, and is designed to remain portable across job changes and life stages, addressing a key gap in existing employer-tied fertility benefits. Co-founder Laura McDonald said the company is building a new category that allows consumers to plan for fertility risk earlier instead of facing large, unplanned expenses once problems arise, reframing fertility as a financial planning decision.

The platform uses proprietary underwriting, individualized risk modeling, AI-driven analytics, and an omnichannel distribution model to make coverage more personalized and cost-efficient, with the goal of improving outcomes while lowering long-term costs. Co-founder Dr. Christy Lane emphasized that earlier access to coverage can improve clinical and financial outcomes, countering the historical view that fertility is uninsurable and highly unpredictable.

Flora’s distribution network already touches more than 10 million prospective policyholders in North America, with policies available directly to consumers or offered via employers while remaining individually owned. In the U.S., coverage starts at about $20 per month and is supported by A-rated insurance carriers and a global reinsurance panel, covering services from diagnostics and medications through IUI and IVF, giving the company a scalable, capital-light model with potential to capture a growing demographic of Gen Z and millennial women who report high fertility-related financial anxiety.

Investor commentary underscores expectations that Flora could define a new category in consumer InsurTech, by combining affordability, inclusivity, and portability for a segment that has historically been underserved by traditional insurance products. For executives and investors, the seed round signals validation of Flora’s model, provides growth capital for product and distribution scaling across the U.S. and Canada, and positions the company to compete as a category creator in the emerging private fertility insurance market.